Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Oct;3(5):915–923. doi: 10.1111/j.1365-2125.1976.tb00647.x

Clinical pharmacokinetic studies of perphenazine.

C Eggert Hansen, T Rosted Christensen, J Elley, L Bolvig Hansen, P Kragh-Sorensen, N E Larsen, J Naestoft, E F Hvidberg
PMCID: PMC1428936  PMID: 973987

Abstract

A gas-chromatographic method was used for the study in man of the kinetics of perphenazine (PPZ) and its sulphoxide metabolite (PPZ-SO). Various forms of PPZ administration were applied in eighteen schizophrenic patients and four healthy volunteers. Following an i.v. dose of 5 or 6 mg a considerable fluctuation in the plasma concentration was noted before the exponential elimination phase. The average terminal half-life of PPZ was approximately 9.5 hours. PPZ-SO showed up quickly but in low concentrations. After an oral dose of 6 mg no PPZ was detected in plasma and PPZ-SO only as traces. During continuous oral medication, 12 mg three times daily, a low systemic availability and a high PPZ-SO/PPZ ratio was found suggesting a marked first pass effect. PPZ-enanthate given i.m. fortnightly resulted in PPZ-levels comparable to those seen after continuous oral medication, but PPZ-SO concentration were much lower. No accumulation was observed. The systemic clearance rate (average approximately 100 1/h) was the same after PPZ-enanthate i.m. and PPZ i.v., but varied three-fold individually. Side effects were mostly, but not always, registered concomitant with high plasma levels of PPZ.

Full text

PDF
915

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Curry S. H., D'Mello A., Mould G. P. Destruction of chlorpromazine during absorption by rat intestine in vitro. Br J Pharmacol. 1970 Nov;40(3):538P–539P. [PMC free article] [PubMed] [Google Scholar]
  2. Curry S. H. Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector. Anal Chem. 1968 Jul;40(8):1251–1255. doi: 10.1021/ac60264a031. [DOI] [PubMed] [Google Scholar]
  3. Gram L. F. Metabolism of tricyclic antidepressants. A review. Dan Med Bull. 1974 Oct;21(6):218–231. [PubMed] [Google Scholar]
  4. Gram L. F., Overo K., Kirk L. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. Am J Psychiatry. 1974 Aug;131(8):863–866. doi: 10.1176/ajp.131.8.863. [DOI] [PubMed] [Google Scholar]
  5. HUANG C. L., KURLAND A. A. PERPHENAZINE (TRILAFON) METABOLISM IN PSYCHOTIC PATIENTS. Arch Gen Psychiatry. 1964 Jun;10:639–646. doi: 10.1001/archpsyc.1964.01720240093010. [DOI] [PubMed] [Google Scholar]
  6. Hansen C. E., Kragh-Sorensen P. Clinical-pharmacological aspects of measuring perphenazine in human blood. Acta Psychiatr Scand Suppl. 1973;246:18–12. doi: 10.1111/j.1600-0447.1973.tb08443.x. [DOI] [PubMed] [Google Scholar]
  7. Hansen C. E., Larsen N. E. Perphenazine concentrations in human whole blood. A pilot study during anti-psychotic therapy using different administration forms. Psychopharmacologia. 1974 Jun 18;37(1):31–36. doi: 10.1007/BF00426680. [DOI] [PubMed] [Google Scholar]
  8. Jorgensen A., Gottfries C. G. Pharmacokinetic studies on flupenthixol and flupenthixol decanoate in man using tritium labelled compounds. Psychopharmacologia. 1972;27(1):1–10. doi: 10.1007/BF00421951. [DOI] [PubMed] [Google Scholar]
  9. Kelsey M. I., Keskiner A., Moscatelli E. A. Gas-liquid chromatographic analysis of fluphenazine and fluphenazine sulfoxide in the urine of chronic schizophrenic patients. J Chromatogr. 1973 Jan 17;75(2):294–297. doi: 10.1016/s0021-9673(00)85557-0. [DOI] [PubMed] [Google Scholar]
  10. Larsen N. E., Naestoft J. Determination of perphenazine and fluphenazine in whole blood by gas chromatography. Med Lab Technol. 1973 Apr;30(2):129–132. [PubMed] [Google Scholar]
  11. Larsen N. E., Naestoft J. Determination of perphenazine and its sulphoxide metabolite in human plasma after therapeutic doses by gas chromatography. J Chromatogr. 1975 Jun 18;109(2):259–264. doi: 10.1016/s0021-9673(01)91797-2. [DOI] [PubMed] [Google Scholar]
  12. Minder R., Schnetzer F., Bickel M. H. Hepatic and extrahepatic metabolism of the psychotropic drugs, chlorpromazine, imipramine, and imipramine-N-oxide. Naunyn Schmiedebergs Arch Pharmakol. 1971;268(3):334–347. doi: 10.1007/BF00997266. [DOI] [PubMed] [Google Scholar]
  13. Mårtensson E., Roos B. E. Serum levels of thioridazine in psychiatric patients and healthy volunteers. Eur J Clin Pharmacol. 1973 Oct;6(3):181–186. doi: 10.1007/BF00558283. [DOI] [PubMed] [Google Scholar]
  14. Rivera-Calimlim L., Castañeda L., Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther. 1973 Nov-Dec;14(6):978–986. doi: 10.1002/cpt1973146978. [DOI] [PubMed] [Google Scholar]
  15. Sakalis G., Chan T. L., Gershon S., Park S. The possible role of metabolites in therapeutic response to chlorpromazine treatment. Psychopharmacologia. 1973 Sep 28;32(3):279–284. doi: 10.1007/BF00422150. [DOI] [PubMed] [Google Scholar]
  16. Simpson G. M., Lament R., Cooper T. B., Lee J. H., Bruce R. B. The relationship between blood levels of different forms of butaperazine and clinical response. J Clin Pharmacol. 1973 Jul;13(7):288–297. doi: 10.1002/j.1552-4604.1973.tb00270.x. [DOI] [PubMed] [Google Scholar]
  17. Sjöqvist F. A pharmacokinetic approach to the treatment of depression. Int Pharmacopsychiatry. 1971;6(3):147–169. doi: 10.1159/000468267. [DOI] [PubMed] [Google Scholar]
  18. Turano P., March J. E., Turner W. J., Merlis S. Qualitative and quantitative report on chlorpromazine and metabolites in plasma, erythrocytes and erythrocyte washings from chronically medicated schizophrenic patients. J Med. 1972;3(2):109–120. [PubMed] [Google Scholar]
  19. Wilkinson G. R. Pharmacokinetics of drug disposition: hemodynamic considerations. Annu Rev Pharmacol. 1975;15:11–27. doi: 10.1146/annurev.pa.15.040175.000303. [DOI] [PubMed] [Google Scholar]
  20. van Kempen G. M. Urinary excretion of perphenazine and its sulfoxide during administration in oral and long-acting injectable form. Psychopharmacologia. 1971;21(3):283–286. doi: 10.1007/BF00403866. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES